Hironori Hozoji
Corporate Officer/Principal presso Jafco Life Science Investment Ltd.
Provenienza dei contatti di primo grado di Hironori Hozoji
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 11 | |
| Public Company | Biotechnology | 11 | |
| Public Company | Pharmaceuticals: Major | 10 | |
| Public Company | Pharmaceuticals: Major | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Hironori Hozoji tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| University of Michigan | College/University | Undergraduate Degree Graduate Degree Undergraduate Degree | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| PFIZER, INC. | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal Corporate Officer/Principal | |
| ALDER BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
Nextech Invest AG
 Nextech Invest AG Investment ManagersFinance Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals. | Investment Managers | Chief Executive Officer Chief Investment Officer | |
ALASTIN Skincare, Inc.
 ALASTIN Skincare, Inc. Household/Personal CareConsumer Non-Durables Alastin Skincare, Inc. develops and markets skin care products that reinvigorate, protect, and maintain healthy skin. It offers skin procedures such as injectables, laser resurfacing, microneedling, peels, photo rejuvination, radio frequency, skin tightening, surgical procedures, and ultra sound therapy. The company was founded by Scott L. Glenn and Cam L. Garner in 2015 and is headquartered in Carlsbad, CA. | Household/Personal Care | Director/Board Member Director/Board Member | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Treasurer General Counsel | |
| University of Basel | College/University | Doctorate Degree Doctorate Degree | |
Memgen, Inc.
 Memgen, Inc. Pharmaceuticals: MajorHealth Technology Memgen, Inc. operates as a clinical-stage biotech company. Its product ISF35, is a viral cancer immunotherapy encoding an optimized version of CD40 ligand. The company was founded by Robert C. Coates and is headquartered in Houston, TX. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ADAMAS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Operating Officer General Counsel | |
SillaJen Biotherapeutics, Inc.
 SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| RELYPSA INC | Pharmaceuticals: Major | Chairman Investor Relations Contact | |
| SIENNA BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Operating Officer Chief Tech/Sci/R&D Officer | |
| AIMMUNE THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Operating Officer Corporate Officer/Principal | |
| GILEAD SCIENCES, INC. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
| University of California, Berkeley | College/University | Doctorate Degree Undergraduate Degree | |
Agouron Pharmaceuticals LLC
 Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Anadys Pharmaceuticals, Inc.
 Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| University of California, Santa Barbara | College/University | Doctorate Degree Doctorate Degree | |
Renagade Therapeutics, Inc.
 Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Biotechnology | Chief Executive Officer | |
Cytrellis Biosystems, Inc.
 Cytrellis Biosystems, Inc. Medical SpecialtiesHealth Technology Cytrellis Biosystems, Inc. designs and develops aesthetic devices. The company was founded by William Gerald Austen and Doug A. Levinson and is headquartered in Boston, MA. | Medical Specialties | Chairman | |
Franklin Templeton Investments Corp.
 Franklin Templeton Investments Corp. Investment ManagersFinance Franklin Templeton Investments Corp. (FTIC) is a SEC-registered investment advisor and mutual fund manager headquartered in Toronto, Canada. The firm was founded in 2000 and is a wholly-owned subsidiary of Templeton International, Inc., ultimately owned by Franklin Resources, Inc. (NYSE: BEN). FTIC provides investment advisory and portfolio management services with clients in jurisdictions worldwide, which include registered open-end and closed-end funds and unregistered funds, as well as separate accounts for institutional and high net-worth clients. | Investment Managers | Corporate Officer/Principal | |
| LUNGLIFE AI, INC. | Medical/Nursing Services | Director/Board Member | |
Percivia LLC
 Percivia LLC Miscellaneous Commercial ServicesCommercial Services Percivia LLC engages in the research and development of vaccine and recombinant protein products. The company was founded in 2006 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Chief Executive Officer | |
| TRILLIUM THERAPEUTICS | Biotechnology | Director/Board Member | |
| Nephrian, Inc. | Founder | ||
Oxeia Biopharmaceuticals, Inc.
 Oxeia Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oxeia Biopharmaceuticals, Inc. is a clinical-stage biotech company, which develops new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging. Its two indications are for (i) mild traumatic brain injury (?mTB?) known as concussion, and (ii) the cognitive decline, lethargy and ?brain-fog? associated with Covid-19 infection, known as Covid Longhauler syndrome (?Long Covid?). The company was founded in 2014 by Vishal Bansal, Amit Dilip Munshi & Kartik Kiran Shah and is headquartered in Boston, MA. | Pharmaceuticals: Major | Founder | |
Onebiopharma, Inc.
 Onebiopharma, Inc. Medical/Nursing ServicesHealth Services Onebiopharma, Inc. provides health care services. The company is headquartered in Boston, MA. | Medical/Nursing Services | Director/Board Member | |
| EPIRUS BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
| Adrista, Inc. | Director/Board Member | ||
| ALLAKOS INC. | Pharmaceuticals: Major | Director/Board Member | |
Orna Therapeutics, Inc.
 Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | Biotechnology | Chief Executive Officer | |
| FRANKLIN RESOURCES, INC. | Investment Managers | Corporate Officer/Principal | |
| ARENA PHARMACEUTICALS | Pharmaceuticals: Major | Chief Executive Officer | |
| GALECTO, INC. | Pharmaceuticals: Major | Director/Board Member | |
| PULMATRIX, INC. | Pharmaceuticals: Major | Director/Board Member | |
| SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. IV | Financial Conglomerates | Director/Board Member | |
| Peter F Drucker & Masatoshi Ito Graduate School of Management | College/University | Masters Business Admin | |
| ZURA BIO LIMITED | Biotechnology | Chairman | |
Enterprise Therapeutics Ltd.
 Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | Biotechnology | Chairman | |
NEA Management Co. LLC
 NEA Management Co. LLC Investment ManagersFinance New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor |
Statistiche
Distribuzione geografica
| Stati Uniti | 44 |
| Svizzera | 5 |
| Canada | 3 |
| Regno Unito | 2 |
Settori
| Health Technology | 30 |
| Consumer Services | 6 |
| Commercial Services | 6 |
| Finance | 6 |
| Health Services | 3 |
Posizioni
| Director/Board Member | 140 |
| Corporate Officer/Principal | 77 |
| Independent Dir/Board Member | 53 |
| Chief Executive Officer | 44 |
| Chairman | 32 |
Contatti più connessi
| Insiders | |
|---|---|
| John P. Walker | 39 |
| Ted Love | 31 |
| Amit Munshi | 27 |
| Dan Spiegelman | 25 |
| Alfred Scheidegger | 20 |
| Paul Cleveland | 18 |
| William LaRue | 15 |
| Sylvia R. Wheeler | 14 |
| François Kress | 13 |
| Stephen Worland | 12 |
| Peter E. Grebow | 12 |
| Elisabeth Sandoval | 12 |
| Martin Mattingly | 10 |
| Paul Lizzul | 10 |
| Jere D. Fellmann | 10 |
- Borsa valori
- Insiders
- Hironori Hozoji
- Connessioni Società
